title: Low dose lithium-carbimazole in the treatment of thyrotoxicosis.
abstract: Fifteen patients with thyrotoxicosis were treated with low dose sustained release lithium carbonate 400 mg, combined with carbimazole 40 mg daily, and the therapeutic response was followed over a two week period. This response was compared with that obtained in a similar group of patient treated with carbimazole alone. Li-carbimazole treatment brought about a fall in the mean total serum T4 of 57.4% compared with a drop of 32.8% in patients treated with carbimazole alone. The mean serum T3 fell by 69.4% in the Li-carbimazole group compared with 47.3% in the group treated with carbimazole only. No lithium adverse effects were encountered.
mesh_terms: D013956:Antithyroid Agents; D002231:Carbimazole / Q000008:administration & dosage*; D003692:Delayed-Action Preparations; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D006980:Hyperthyroidism / Q000188:drug therapy*; D008094:Lithium / Q000008:administration & dosage*; D013974:Thyroxine / Q000097:blood; D014284:Triiodothyronine / Q000097:blood
chemical_list: D013956:Antithyroid Agents; D003692:Delayed-Action Preparations; D014284:Triiodothyronine; D002231:Carbimazole; D008094:Lithium; D013974:Thyroxine